Journal of Applied Physiology, Vol 73, Issue 1 317-323, Copyright © 1992 by American Physiological Society

ARTICLES

Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defense

P. Birrer, N. G. McElvaney, A. Gillissen, R. F. Hoyt, D. C. Bloedow, R. C. Hubbard and R. G. Crystal
Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.

Secretory leukoprotease inhibitor (SLPI), a 12-kDa serine antiprotease, normally protects the upper airway epithelial surface from attack by neutrophil elastase (NE). In the context that a variety of inflammatory lung diseases are characterized by large neutrophil burdens with resultant high levels of NE in the lung, recombinant SLPI (rSLPI), a molecule identical to natural SLPI, may be an effective means to augment the anti-NE protective screen of the lung. To determine whether intravenous rSLPI will augment respiratory tract and epithelial surface levels of SLPI and anti-NE capacity, rSLPI was administered intravenously to sheep and SLPI levels were quantified in plasma, lung lymph (as a measure of lung interstitial levels), lung epithelial lining fluid (ELF), and urine. rSLPI (1 g) was administered over 10 min, and after 30 min plasma levels of SLPI were 8 microM and decreased with a half-life of 1.8 h. Lymph SLPI levels paralleled the plasma levels: 4 h after infusion the lymph-to-plasma ratio was 0.8. ELF SLPI levels paralleled the lymph levels: 4 h after infusion the ELF-to-lymph ratio was 0.3. Western analysis demonstrated intact SLPI in lymph and ELF, and functional analysis showed increases in lymph and ELF anti-NE capacity that paralleled the levels of SLPI. As might be expected from a protein with a molecular mass of 12 kDa, urine excretion was high, with 20% of the SLPI excreted over 5 h. However, if the rate of infusion was slowed, SLPI excretion decreased significantly, with a 3-h infusion associated with 9% excretion and a 12-h infusion associated with less than 0.2% excretion.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				M. Griese, M. Kappler, A. Gaggar, and D. Hartl Inhibition of airway proteases in cystic fibrosis lung disease Eur. Respir. J., September 1, 2008; 32(3): 783 - 795. [Abstract] [Full Text] [PDF]

				American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 818 - 900. [Full Text] [PDF]

				M. S. Pate, S. R. Hedges, D. A. Sibley, M. W. Russell, E. W. Hook III, and J. Mestecky Urethral Cytokine and Immune Responses in Chlamydia trachomatis-Infected Males Infect. Immun., November 1, 2001; 69(11): 7178 - 7181. [Abstract] [Full Text] [PDF]

				T. S. Gipson, N. M. Bless, T. P. Shanley, L. D. Crouch, M. R. Bleavins, E. M. Younkin, V. Sarma, D. F. Gibbs, W. Tefera, P. C. McConnell, et al. Regulatory Effects of Endogenous Protease Inhibitors in Acute Lung Inflammatory Injury J. Immunol., March 15, 1999; 162(6): 3653 - 3662. [Abstract] [Full Text] [PDF]

				B. D. Levine, J. A. Pawelczyk, A. C Ertl, J. F. Cox, J. H. Zuckerman, A. Diedrich, I. Biaggioni, C. A. Ray, M. L. Smith, S. Iwase, et al. Human muscle sympathetic neural and haemodynamic responses to tilt following spaceflight J. Physiol., January 1, 2002; 538(1): 331 - 340. [Abstract] [Full Text] [PDF]